RxDoctor Payments Data

Sandeep Patel, MD

Cardiovascular Disease · Lima, OHNPI 1336379635

Payments from drug & device makers

$152,299in general payments, 2019–2025

Across 591 payments — averaging $257.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$60K
  • Johnson & Johnson$41K
  • Livanova USA, Inc.$27K
  • Boston Scientific$11K
  • Abbott$9K
  • Abiomed$858
  • plus $4K from 41 others

What the payments were for

  • Consulting fees$1,6881%
  • Speaking & faculty fees$117,53577%
  • Grants$1230%
  • Travel & lodging$19,62813%
  • Food & beverage$13,2249%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$152,299 in reported general payments places this provider in the 90th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$520,320
Medicare patients
2,012
Services billed
6,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban226$275,505
XareltoRivaroxaban166$202,917
EntrestoSacubitril/Valsartan131$130,689
BrilintaTicagrelor110$89,572
Repatha SureclickEvolocumab49$66,170
JardianceEmpagliflozin42$60,950
FarxigaDapagliflozin Propanediol16$23,943
Metoprolol Succinate460$6,685
ClopidogrelClopidogrel Bisulfate489$5,650
Atorvastatin Calcium470$4,783
Ranolazine ErRanolazine51$4,265
Diltiazem 12hr ErDiltiazem Hcl11$3,474
Amiodarone Hcl58$3,096
Isosorbide Mononitrate ErIsosorbide Mononitrate241$2,802
Enoxaparin Sodium12$1,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$186$275,505226 claims
Johnson & JohnsonXarelto$41,452$202,917166 claims
NovartisEntresto$599$130,689131 claims
AstraZenecaBrilinta, Farxiga$12$113,515126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →